title: Methods for Evaluating Cell-Specific, Cell-Internalizing RNA Aptamers.
abstract: Recent clinical trials of small interfering RNAs (siRNAs) highlight the need for robust delivery technologies that will facilitate the successful application of these therapeutics to humans. Arguably, cell targeting by conjugation to cell-specific ligands provides a viable solution to this problem. Synthetic RNA ligands (aptamers) represent an emerging class of pharmaceuticals with great potential for targeted therapeutic applications. For targeted delivery of siRNAs with aptamers, the aptamer-siRNA conjugate must be taken up by cells and reach the cytoplasm. To this end, we have developed cell-based selection approaches to isolate aptamers that internalize upon binding to their cognate receptor on the cell surface. Here we describe methods to monitor for cellular uptake of aptamers. These include: (1) antibody amplification microscopy, (2) microplate-based fluorescence assay, (3) a quantitative and ultrasensitive internalization method ("QUSIM") and (4) a way to monitor for cytoplasmic delivery using the ribosome inactivating protein-based (RNA-RIP) assay. Collectively, these methods provide a toolset that can expedite the development of aptamer ligands to target and deliver therapeutic siRNAsin vivo.
authors.affiliation: Department of Internal Medicine, University of Iowa, Iowa City, IA 52242, USA.
authors.forename: Luiza I
authors.initials: LI
authors.lastname: Hernandez
authors.forename: Katie S
authors.initials: KS
authors.lastname: Flenker
authors.forename: Frank J
authors.initials: FJ
authors.lastname: Hernandez
authors.forename: Aloysius J
authors.initials: AJ
authors.lastname: Klingelhutz
authors.forename: James O
authors.initials: JO
authors.lastname: McNamara
authors.forename: Paloma H
authors.initials: PH
authors.lastname: Giangrande
keywords: RNA aptamers; cell-SELEX; cell-internalizing aptamers; siRNA delivery; targeted delivery
references.citation: Int J Pept Protein Res. 1989 Apr;33(4):263-7
references.pmid: 2753596
references.citation: Br J Haematol. 1998 Sep;102(4):1061-8
references.pmid: 9734659
references.citation: Oligonucleotides. 2009 Sep;19(3):209-22
references.pmid: 19653880
references.citation: J Control Release. 2011 May 10;151(3):220-8
references.pmid: 21078351
references.citation: Curr Top Med Chem. 2009;9(12):1144-57
references.pmid: 19860714
references.citation: Chem Biol. 2012 Jan 27;19(1):60-71
references.pmid: 22284355
references.citation: J Clin Invest. 2011 Jun;121(6):2383-90
references.pmid: 21555850
references.citation: FEBS Lett. 1992 Feb 24;298(2-3):145-8
references.pmid: 1544437
references.citation: J Immunol. 1988 Nov 15;141(10):3662-70
references.pmid: 3141503
references.citation: Ther Deliv. 2010 Dec;1(6):849-61
references.pmid: 21643487
references.citation: Nucleic Acid Ther. 2012 Feb;22(1):58-68
references.pmid: 22229275
references.citation: Int J Cancer. 1998 Sep 11;77(6):937-41
references.pmid: 9714068
references.citation: Mol Pharmacol. 2012 Oct;82(4):623-35
references.pmid: 22752556
references.citation: Nat Biotechnol. 2009 Sep;27(9):839-49
references.pmid: 19701187
references.citation: Nucleic Acids Res. 2006 Jun 01;34(10):e73
references.pmid: 16740739
references.citation: Nucleic Acid Ther. 2011 Jun;21(3):173-8
references.pmid: 21749294
references.citation: Nature. 2010 May 13;465(7295):227-30
references.pmid: 20463739
references.citation: Sci Transl Med. 2011 Jan 19;3(66):66ra6
references.pmid: 21248316
references.citation: Biochem Biophys Res Commun. 1985 Jun 28;129(3):934-42
references.pmid: 3925952
references.citation: Mol Ther. 2012 Mar;20(3):483-512
references.pmid: 22186795
references.citation: Nucleic Acids Res. 2009 May;37(9):3094-109
references.pmid: 19304999
references.citation: Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2012 Jul-Aug;4(4):428-37
references.pmid: 22228711
references.citation: Scand J Immunol. 1989 Sep;30(3):369-72
references.pmid: 2571186
references.citation: Biotechnology (N Y). 1992 Apr;10(4):405-12
references.pmid: 1368484
references.citation: J Biol Chem. 1987 May 15;262(14):6494-9
references.pmid: 2952651
references.citation: Science. 1990 Aug 3;249(4968):505-10
references.pmid: 2200121
references.citation: Br J Cancer. 1995 May;71(5):986-94
references.pmid: 7734325
references.citation: Front Genet. 2012 Nov 02;3:234
references.pmid: 23130020
references.citation: Mol Ther. 2013 Jan;21(1):192-200
references.pmid: 23164935
references.citation: Nucleic Acid Ther. 2011 Oct;21(5):299-314
references.pmid: 22004414
references.citation: Int J Cancer. 2000 Jul 15;87(2):186-94
references.pmid: 10861472
references.citation: Nucleic Acids Res. 2012 Jul;40(13):6319-37
references.pmid: 22467215
references.citation: PLoS One. 2012;7(9):e43836
references.pmid: 22962591
references.citation: Curr Protoc Pharmacol. 2002 Feb;Chapter 3:Unit3.10
references.pmid: 21959764
references.citation: Nat Rev Drug Discov. 2010 Jul;9(7):537-50
references.pmid: 20592747
references.citation: J Biol Chem. 1987 Apr 25;262(12):5908-12
references.pmid: 3571242
references.citation: Nature. 1990 Aug 30;346(6287):818-22
references.pmid: 1697402
references.citation: Nucleic Acid Ther. 2011 Aug;21(4):253-63
references.pmid: 21793789
references.citation: J Clin Invest. 2011 Jun;121(6):2401-12
references.pmid: 21576818
references.citation: J Clin Invest. 2008 Jan;118(1):376-86
references.pmid: 18060045
references.citation: Mol Ther. 2008 Aug;16(8):1481-9
references.pmid: 18461053
references.citation: Nat Biotechnol. 2006 Aug;24(8):1005-15
references.pmid: 16823371
references.citation: Cancer Res. 2002 Jul 15;62(14):4029-33
references.pmid: 12124337